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Background: The signaling pathways most critical to prion disease pathogenesis are as yet incompletely
characterized. We have developed a kinomics approach to identify signaling pathways that are dysregulated during
prion pathogenesis. The approach is sensitive and specific enough to detect signaling pathways dysregulated in a
simple in vitro model of prion pathogenesis. Here, we used this approach to identify signaling pathways
dysregulated during prion pathogenesis in vivo.
Methods: Mice intraperitoneally infected with scrapie (strain RML) were euthanized at 70, 90, 110, 130 days
post-infection (dpi) or at terminal stages of disease (155–190 dpi). The levels of 139 protein kinases in
brainstem-cerebellum homogenates were analyzed by multiplex Western blots, followed by hierarchical clustering
and analyses of activation states.
Results: Hierarchical and functional clustering identified CaMK4β and MST1 signaling pathways as potentially
dysregulated. Targeted analyses revealed that CaMK4β and its downstream substrate CREB, which promotes
neuronal survival, were activated at 70 and 90 dpi in cortical, subcortical and brainstem-cerebellum homogenates
from scrapie-infected mice. The activation levels of CaMK4β/CREB signaling returned to those in mock-infected mice
at 110 dpi, whereas MST1, which promotes neuronal death, became activated at 130 dpi.
Conclusion: Pro-survival CaMK4β/CREB signaling is activated in mouse scrapie at earlier times and later inhibited,
whereas pro-death MST1 signaling is activated at these later times.
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Prion diseases are a family of invariably lethal chronic
neurodegenerative diseases that affect humans (kuru;
Creutzfeldt-Jakob disease, CJD; Gerstmann-Sträussler-
Scheinker disease, GSS; fatal familial insomnia, FFI),
and other species such as cattle (bovine spongiform en-
cephalopathy, BSE), goat, sheep (scrapie), deer, elk and
moose (chronic wasting disease, CWD) [1,2]. Human
prion diseases can be infectious (acquired), inherited
(genetic), or sporadic. The latter are the most common,
accounting for approximately 85% of cases [3]. Whereas* Correspondence: luis.schang@ualberta.ca
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from the risk facts, before the onset of clinical symp-
tom, the sporadic cases can only be diagnosed after the
onset of clinical symptoms [4].
The neuropathology of prion diseases is character-
ized by gliosis, spongiform degeneration, and neuronal
death. The conversion of the cellular prion protein
(PrPC) into its pathological conformation (PrPSc) is es-
sential for pathogenesis. Neuronal death and disease
progression were prevented in scrapie-infected mice by
conditional ablation of PrPC at the time when PrPSc
was first detected [5]. Inhibition of PrPC conversion to
PrPSc is thus a validated target for therapeutic inter-
vention. Many compounds have been identified to in-
hibit PrP conversion or the accumulation of PrPSc
in vitro [6,7]. Only one, however, the diphenyl pyrazoletd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
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mophenyl)-1H-pyrazole], prolonged survival of scrapie-
infected mice when treatment was started after the onset
of clinical signs of disease [8]. Unfortunately, none affected
survival of patients with CJD, GSS, or FFI [9-18]. Another
compound that prolonged survival of scrapie-infected
mice after the onset of clinical disease is the calcineurin/
protein phosphatase 3 inhibitor FK506. FK506, however,
did not affect the levels of PrPC or the accumulation of
PrPSc [19], indicating that FK506 acts downstream from
the accumulation of PrPSc. As FK506 is a known (calcine-
urin) signaling inhibitor, these results suggest that dysreg-
ulated signaling downstream of PrP conversion is an
alternative therapeutic target against prion diseases.
Protein kinases (and phosphatases) modulate by revers-
ible phosphorylation the function, localization, or activities
of approximately one-third of cellular proteins [20]. Protein
kinases are therefore critical regulators of signal transduc-
tion. Their dysregulation is implicated in the pathogenesis
of many chronic diseases, including neurodegenerative dis-
eases such as Alzheimer’s and Parkinson’s [21-23]. Conse-
quently, protein kinases are major therapeutic targets. It is
estimated that up to 30% of the research and development
budget of the pharmaceutical industry is invested in pro-
tein kinase inhibitors [24,25]. For example, protein kinase
inhibitors are the largest group of new cancer therapeutics
[26]. Thirty-one protein kinase inhibitors are in clinical
use, over 500 are involved in approximately 2,700 clinical
trials, and thousands more are in various stages of pre-
clinical development ([26-28] and summary of [29]). Pro-
tein kinase inhibitors therefore constitute a rapidly growing
group of clinical drugs that have the potential to consider-
ably impact treatment of chronic diseases.
Considering the critical roles that protein kinases play in
the pathogenesis of other chronic neurodegenerative dis-
eases, it is not surprising that they also participate in the
pathogenesis of prion diseases. For example, the activation
of vascular endothelial growth factor receptor (VEGFR)
inhibited death of cultured neurons treated with the neuro-
toxic prion peptide PrP106-126 [30]. Death of PrP106-126-
treated cultured neurons was also inhibited by Abelson
leukemia oncogene cellular homolog (c-Abl) knockdown
[31] and treatment with the glycogen synthase kinase 3
(GSK3) inhibitor lithium [32]. Scrapie-infected mice treated
with the protein kinase R-like endoplasmic reticulum kin-
ase (PERK) inhibitor GSK2606414 survived longer than
vehicle-treated mice [33]. The phosphoinositide-dependent
kinase 1 (PDK1) inhibitor BX912 also prolonged survival of
scrapie-infected mice [34]. Protein kinase inhibitors may
have good potential in prion disease therapeutics. Unfortu-
nately, the signaling pathways most critical to prion disease
pathogenesis have yet to be fully identified.
We have developed a kinomics approach to identify
signaling pathways dysregulated during prion diseasepathogenesis (Shott et al., companion paper). We ini-
tially tested the approach in a simplified in vitro model
of prion disease pathogenesis (Shott et al., companion
paper). Here, we applied the approach to mice infected
with mouse-adapted scrapie. We identified two signal-
ing pathways dysregulated during scrapie pathogenesis.
The calcium/calmodulin-dependent protein kinase, beta
isoform (CaMK4β)/cAMP response element-binding pro-
tein (CREB) signaling pathway, which promotes neuronal
survival, was activated at earlier times but its activation
state returned to that in mock-infected mice later on.
Mammalian STE20-like protein kinase 1 (MST1) signal-
ing, which promotes neuronal death, was, in contrast, acti-
vated at these later times. The dysregulation of CaMK4β/
CREB and MST1 signaling pathways may therefore be
critical to the neurodegeneration in scrapie infected mice.
Results
PrPres is first detected in scrapie-infected mice at 130 dpi
Mock-infected mice or mice infected intraperitoneally
with scrapie (mouse-adapted strain RML) were eutha-
nized at 70, 90, 110, 130 days post-infection (dpi), or at
terminal stages of disease (155–190 dpi). Brains were
dissected into (i) cortical (cerebrum), (ii) subcortical (in-
cluding thalamus, hypothalamus and hippocampus) and
(iii) brainstem-cerebellum as described [35].
We first analyzed the levels of protease-resistant PrPSc
(PrPres) and total glial fibrillary acidic protein (GFAP) by
Western blot. PrPres was enriched by sodium phospho-
tungstic acid (NaPTA) precipitation prior to proteinase K
(PK) treatment. As expected, PrPres was only detected in
scrapie-infected mice, and its levels increased with time of
infection (Figure 1A). PrPres was first detected in all regions
at 130 dpi, and increased coordinately with the levels of
GFAP from 130 dpi to terminal stages of disease (unpaired
two-tail t-test; GFAP brainstem-cerebellum, P = 0.0388;
subcortical region, P = 0.0008; cortical region, P = 0.0414)
(Figure 1B), as expected [36,37]. The levels of GFAP were
also higher in the brainstem-cerebellum of scrapie-infected
mice prior to PrPres accumulation at 70 dpi (P = 0.0041)
and showed a tendency to higher levels in the cortical re-
gion at 90 dpi, as observed previously [38]. The lower mo-
lecular weight form of GFAP has also been observed
previously [39] and is likely the result of degradation.
Primary kinomic screens identified two signaling
pathways of potential interest, which are involved in
neuronal death and survival
After intraperitoneal infection, prion disease spreads in
the brain caudal to rostral [40-42]. We therefore selected
the brainstem-cerebellum for the primary screens, for
the greatest window of opportunity to identify signaling
pathways dysregulated during pathogenesis. Primary
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Figure 1 Levels of GFAP and PrPres during scrapie progression. (A) Western blots of GFAP, total PrP, and PrPres in homogenates of
brainstem-cerebellum, subcortical region, and cortical region of three mock (Mock)- or scrapie (RML)-infected mice at 70, 90, 110, 130 dpi or at
terminal stage of disease (155–190 dpi). Molecular weights in kDa are indicated on the left. Black triangles, samples in which PrPres was quantitated.
(B) Time-course changes in the levels of GFAP and PrPres. Line graphs show the levels of GFAP in scrapie-infected mice normalized to the average
levels in mock-infected mice at each time point. The levels of PrPres are expressed as a percentage relative to the highest level detected in each region.
Mean ± SD; n = 3 (Mean ± range for PrPres at 130 dpi where n = 2). Error bars on the x-axis, range in time of onset of terminal disease. The differences in
GFAP levels in scrapie- versus mock-infected mice were analyzed by unpaired two-tail t-test. *P < 0.05; **P < 0.01; ***P < 0.001.
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http://www.virologyj.com/content/11/1/160of 139 protein kinases (Additional file 1: Table S1) in
brainstem-cerebellum homogenates of three mock-infected
and three scrapie-infected mice euthanized at 70, 90, 110,
130 dpi or at terminal stages (155–190 dpi). The antibodies
included in our analyses were optimized and validated asdescribed (Shott et al., companion paper). We detected
109 protein kinases (78% of the 139 tested), most of which
were differentially expressed in scrapie- as compared to
mock-infected mice. For example, CaMK4β was expressed
to higher levels in scrapie- than in mock-infected mice at
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to lower levels at 130 dpi (Figure 2B). Ten protein kinases
were not detected in one set of mock- and scrapie-infected
mice at one time point (tropomyosin-related kinase B
[TrkB], Set 1 at 70 dpi; membrane-associated tyrosine/
threonine-specific cdc2-inhibitory kinase [Myt1], Set 2 at
110 dpi; v-Raf murine sarcoma viral oncogene homolog B1
[B-Raf], ribosomal protein S6 kinase, 70 kilodalton, poly-
peptide 1 [p70S6K], serine/threonine-protein kinase D3
[PKD3], protein kinase R [PKR], serine/threonine-protein
kinase N2 [PRK2], STE20-like serine/threonine-protein
kinase [SLK], TRAF2 and NCK-interacting protein kinase
[TNIK], and tropomyosin-related kinase C [TrkC], Set 3
at 130 dpi). Five other proteins (calcium/calmodulin-
dependent protein kinase 1 alpha [CaMK1α], cyclin D1,
cyclin G1, p25 and p35) were not resolved in one set at
70, 90, 110, and 130 dpi. Mitogen-activated protein kinase
kinase kinase 5 (ASK1) and mitogen-activated protein kin-
ase kinase kinase 1 (MEKK1) were not quantitated in one
set at 90 dpi, or two at terminal stages, due to transfer or
blotting artifacts, respectively. The raw densitometric data
obtained from all other protein kinases was normalized to
data from the mock-infected mice, log2 transformed and
analyzed by unsupervised hierarchical clustering.
We first blindly clustered the scrapie-infected mice to
evaluate the changes in protein kinase expression during
disease progression (Figure 3). The most distantly related
cluster consisted of the two mice euthanized at 130 dpi
with the highest levels of PrPres, and one mouse eutha-
nized at terminal stages of disease (130–1, 130–2, TER-1).
The second most distantly related cluster consisted of two
mice euthanized at 70 dpi (70–2, 70–3). All other mice
clustered in two subclusters. One of them consisted of the
third mouse euthanized at 70 dpi (70–1), two mice eutha-
nized at 90 dpi, and all three mice euthanized at 110 dpi.
The other consisted of mice euthanized at 90 dpi, 130
dpi, and terminals stages of disease (90–1, 130–3, TER-
2, TER-3). The mice therefore clustered largely based
on time after infection, suggesting that levels of protein
kinase expression in mice changed in response to scra-
pie pathogenesis.
The data was next clustered to identify the expression
levels of protein kinases which changed similarly in scrapie-
infected mice during disease progression (Figure 4A). Pro-
tein kinases with similar changes in expression may, or may
not, also be involved in the same signaling pathway. To
identify those that were, we performed literature and signal
transduction database searches. Mitogen-activated protein
kinase 12 (p38γ), ribosomal S6 kinase 1 (RSK1), v-yes-1
Yamaguchi sarcoma viral related oncogene homolog (Lyn),
and CaMK4β, which clustered together because they were
expressed to similarly higher levels in scrapie- than in
mock-infected mice at 70 dpi, are all involved in an N-
methyl-D-aspartate receptor (NMDAR)-regulated CaMK4βsignaling pathway that promotes neuronal survival
(Figure 4B, i). MST1, DLK and mitogen-activated protein
kinase 9 (JNK2) (p54; α2/β2 isoforms), which clustered to-
gether because they were expressed to similarly lower
levels in scrapie- than in mock-infected mice at 130 dpi,
are all involved in an MST1 signaling pathway that pro-
motes neuronal death (Figure 4B, ii). Although dual speci-
ficity mitogen-activated protein kinase kinase 7 (MKK7),
which is also involved in this pathway, clustered distantly,
its expression levels were also somewhat lower in scrapie-
than in mock-infected mice at 130 dpi.
Primary screens of brainstem-cerebellum homogenates
from scrapie-infected mice therefore identified two signal-
ing pathways which may be dysregulated during pathogen-
esis. The NMDAR-regulated CaMK4β signaling pathway
promotes neuronal survival and the expression levels of
the protein kinases involved changed (increased) the most
at earlier times. Conversely, the MST1 signaling pathway
promotes neuronal death, and the expression levels of in-
volved protein kinases were most affected (decreased) at
later times.
CaMK4β/CREB signaling is activated at early stages of
scrapie in mice
The NMDAR-regulated CaMK4β signaling pathway pro-
motes neuronal survival though the activation of CREB
[43]. We therefore analyzed the expression levels of CREB.
We also analyzed the expression levels of neuronal nitric
oxide synthase (nNOS) and the scaffold protein post-
synaptic density protein 95 (PSD-95), which associate with,
or are regulated by, RSK1, Lyn and p38γ at NMDARs
[44-46]. CaMK4β, CREB, p38γ, RSK1, and PSD-95 levels in
the brainstem-cerebellum of scrapie-infected mice were dif-
ferent from those in mock-infected mice (nonlinear regres-
sion analysis; CaMK4β, P = 0.0404; CREB, P = 0.0372; p38γ,
P = 0.0369; RSK1, P = 0.0471; PSD-95, P = 0.0147) (Figure 5).
Consistent with the higher levels of RSK1, Lyn, p38γ, and
CaMK4β in the brainstem-cerebellum of scrapie-infected
mice at 70 dpi, the levels of nNOS and CREB were also
higher at this time (two-tail paired ratio t-test; nNOS, P =
0.0434; CREB, P = 0.0341) (Figure 5). We expanded our
analyses to the subcortical and cortical regions. CREB levels
were also significantly higher in the subcortical and cortical
regions of scrapie-infected mice, but at 90 dpi (subcortical
region, P = 0.0196; cortical region, P = 0.0481) (Figure 5).
CaMK4β and CREB levels changed coordinately in
both the brainstem-cerebellum and subcortical regions
(Figure 5).
We next performed targeted tertiary (phosphorylation
state-specific) analyses to characterize the activation state of
(NMDAR-regulated) CaMK4β/CREB signaling in scrapie-
infected mice. The activation of Lyn and RSK1 involves au-
tophosphorylation on Y396 or S380, respectively [47-50].
Activated RSK1 (P-S380) inhibits nNOS by phosphorylation
AB
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Figure 2 (See legend on next page.)
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Figure 2 Differential expression of protein kinases in scrapie- versus mock-infected mice at 70 and 130 dpi. Primary multiplex Western
blots analyzing the expression levels of 139 protein kinases in three mock- or scrapie-infected mice at 70 (A) or 130 (B) dpi. Mice identified by
ID numbers; M, mock-infected; RML, RML-infected. Molecular weights in kDa are indicated on the left. The protein kinases CaMK4β (A; probed
with antibody set 1) and DLK (B; probed with antibody set 2) are indicated by white arrowheads and enlarged to illustrate their differential
expression in scrapie- versus mock-infected mice. The antibody used to detect CaMK4β also detects CaMK4 (red band, indicated by the asterisks),
the levels of which remain constant. The expression levels of the other protein kinases tested in the same or adjacent lanes also remained
constant or were expressed differently than CaMK4β and DLK (A, CK1ε [red band] indicated by 1; B, LIMK1 indicated by 1 and GSK3α indicated
by 2). Apparent signal above GSK3α in mouse ID 11 M is an artifact.
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PSD-95 on S290 [46]. Activated CaMK4β (P-T196; corre-
sponding to human T200) phosphorylates CREB on S133
[51,52]. Phosphorylated CREB promotes transcription of
genes that encode proteins involved in neuronal survival
[53,54]. There is no antibody specific for T180/Y182 phos-
phorylation on only p38γ. We therefore used an antibody
that detects T180/Y182 phosphorylation on all p38 iso-
forms (p38α, p38β, p38γ, p38δ). In summary, we analyzed
the levels of activating phosphorylation of p38 (P-T180/
Y182), Lyn (P-Y396), RSK1 (P-S380), CaMK4β (P-T196),
and CREB (P-S133), and the levels of inhibitory phosphor-
ylation of nNOS (P-S847). No antibody specific for p38-
phosphorylated PSD-95 (P-S290) was available.
As their total levels, the levels of activated CaMK4β (P-
T196) and CREB (P-S133) changed coordinately. Their
levels were significantly higher in the brainstem-cerebellum
of scrapie-infected than of mock-infected mice at 70 and
90 dpi (two-tail paired ratio t-test; CaMK4β P = 0.0256 [70
dpi], 0.0248 [90 dpi]; CREB P = 0.0197 [70 dpi], 0.0086 [90
dpi]) (Figure 6). The levels of phosphorylated CREB in the
subcortical and cortical regions were also significantly
higher (subcortical region P = 0.0412 [90 dpi]; cortical re-
gion P = 0.0093 [70 dpi], 0.0376 [90 dpi]), or at least there
was a trend to higher levels in scrapie-infected than in
mock-infected mice (subcortical region P = 0.0936 [70 dpi])
(Figure 6). The levels of activated CaMK4β in thePr
Figure 3 Blind clustering of scrapie-infected mice results in their grou
scrapie-infected mice euthanized at 70, 90, 110, 130 dpi or at terminal stag
kinases detected in primary multiplex Western blots. The normalized and lo
(1, 2, 3 - consisting of one scrapie-and one mock-infected mouse euthanize
(Euclidean distance; complete linkage) and presented using Java Treeview.subcortical and cortical regions at 70 and 90 dpi were simi-
lar in scrapie- and mock-infected mice. The levels of acti-
vated p38 (P-T180/T182) were significantly higher in
scrapie-infected than in mock-infected mice at 70 and 90
dpi (brainstem-cerebellum P = 0.0225 [90 dpi]; subcortical
region P = 0.0106 [70 dpi]; cortical region P = 0.0014 [70
dpi]) but also at 110 and 130 dpi (brainstem-cerebellum
P = 0.0465 [110 dpi]; cortical region P = 0.0116 [130 dpi])
(Figure 6). There was no correlation between the levels of
activated RSK1 (P-S380) and nNOS (P-S847) in the differ-
ent brain regions (Additional file 2: Figure S1). The levels
activated Lyn (P-Y396) were mostly unchanged in scrapie-
infected mice relative to mock-infected mice.
In summary, CaMK4β/CREB signaling was activated
in scrapie-infected mice at early times. The expression
levels and the levels of phosphorylated CREB (P-S133)
and activated CaMK4β (P-T196) were higher in scrapie-
than in mock-infected mice at 70 and 90 dpi.
MST1 is activated at late stages of mouse scrapie
The MST1 signaling pathway mediates neuronal death by
activating forkhead box protein O3 (FOXO3) [55]. We
therefore analyzed the expression levels of FOXO3 in tar-
geted secondary Western blots of brainstem-cerebellum
homogenates from scrapie-infected mice at 70, 90, 110,
130 dpi or at terminal stages of disease. Consistent with
















ping largely by time after infection. Hierarchical clustering of the
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Figure 4 (See legend on next page.)
Shott et al. Virology Journal 2014, 11:160 Page 7 of 21
http://www.virologyj.com/content/11/1/160
(See figure on previous page.)
Figure 4 Identification of two signaling pathways of potential interest involved in neuronal survival and death. (A) Hierarchical
clustering the normalized and log2 transformed densitometric data of the expression levels of 109 protein kinases detected in primary multiplex
Western blots of brainstem-cerebellums of scrapie-infected mice at 70, 90, 110, 130 dpi or at terminal stage of disease (TER). Red, higher expression
level; green, lower expression level; grey, no data (protein kinases that were not resolved, not detected, or not quantitated due to transfer or blotting
artifacts). Cluster (i) consists of protein kinases involved in the NMDAR-regulated CaMK4β signaling pathway. Cluster (ii) consists of protein kinases
involved in the MST1 signaling pathway. The protein kinases highlighted in Figure 2, CaMK4β and DLK, are indicated by (●), and MKK7 is indicated by
(◄). (B) Expression levels of protein kinases involved in the CaMK4β and MST1 signaling pathways, and included in the primary multiplex Western
blots, at 70 dpi (top panel) and 130 dpi (bottom panel), respectively. Color bars indicate the levels in each of the three scrapie-infected mice normalized
to those in mock-infected mice.
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0.0095), FOXO3 levels were also significantly lower (P <
0.0001) in the brainstem-cerebellum of scrapie- than of
mock-infected mice at 130 dpi (Figure 7). The levels of
DLK, MKK7, and JNK2 were more similar in the
subcortical and cortical regions of mock- and scrapie-
infected mice than in their brainstem-cerebellum
(Figure 7) (Additional file 3: Figure S2). However, MST1
and FOXO3 were still expressed to significantly lower
levels in the cortical region of scrapie- than of mock-
infected mice at 130 dpi (MST1, P = 0.0384; FOXO3, P =
0.0090) (Figure 7). MST1 levels also appeared to be differ-
ent in the subcortical region of scrapie- or mock-infected
mice (nonlinear regression analysis; MST1, P = 0.0513),
but did not reach statistical significance at any single time
point. The differential expression of MST1 and FOXO3 in
the brainstem-cerebellum and cortical region, albeit to dif-
fering degrees, supports a model in which MST1/FOXO3
signaling is dysregulated during progression of scrapie.
To test this model, we performed targeted (phosphoryl-
ation state-specific) tertiary Western blots to characterize
the activation state of MST1/FOXO3 signaling. MST1 is
activated by autophosphorylation on T183 (P-T183) [56].
Activated MST1 phosphorylates FOXO3 in the cytosol on
S208 (corresponding to S207 in human) [55]. Phosphory-
lated FOXO3 (P-S208) then translocates to the nucleus
where it activates transcription of genes that encode pro-
teins involved in neuronal death. Activated MST1 is further
activated by caspase-3 cleavage. Cleaved MST1 further
promotes cell death [57-60]. We analyzed the levels of acti-
vating phosphorylation of MST1 (P-T183) and FOXO3
(P-S207) and activating cleavage of MST1. MST1 activation
is promoted by JNK-mediated phosphorylation on S82 [61]
and active JNK2 is phosphorylated on T183/Y185. As no
antibody available was specific for P-T183/Y185 of only
JNK2 or P-S82 of MST1, we used antibodies that detect
T183/Y185 phosphorylation on all JNK isoforms (JNK1,
JNK2, JNK3; p46 [JNK1α1, JNK1β1, JNK2α1, JNK2β1,
JNK3α1] and p54 [JNK1α2, JNK1β2, JNK2α2, JNK2β2,
JNK3β2]) or autophosphorylated MST1 (P-T183).
There was a trend to higher levels of activated JNK (p54;
P-T183/Y185) and MST1 (P-T183) in the cortical region of
scrapie-infected mice at 70 dpi (two-tail paired ratio t-test;
JNK [p54], P = 0.0851; MST1, P = 0.0880) (Figure 8). Thelevels of activated JNK were significantly higher in the
subcortical region at 70 dpi (P = 0.0332), whereas those of
MST1 were not (P = 0.2222). Cleaved MST1 and phosphor-
ylated FOXO3 (P-S208) levels were similar in scrapie- and
mock-infected mice at this time (Additional file 3: Figure S2).
Levels of cleaved MST1 were significantly higher at 130
dpi in all brain regions (brainstem-cerebellum, P = 0.0452;
subcortical region, P = 0.0237; cortical region, P = 0.0243),
whereas activated JNK levels were similar in scrapie- and
mock-infected mice at this time (Figure 8). Levels of acti-
vated MST1 (P-T183) were significantly higher (P = 0.0215)
in the cortical region of scrapie-infected mice at terminal
stages, when the levels of cleaved MST1 had returned to
levels similar to those in mock-infected mice.
In summary, MST1 signaling was activated in scrapie-
infected mice at late times. Levels of cleaved MST1 were
higher at 130 dpi, when total levels of MST1 and FOXO3
were lower. At terminal stages of disease, levels of acti-
vated MST1 (P-T183) were higher in scrapie- than in
mock-infected mice.
Discussion
We describe the application of a new kinomics approach
to an in vivo model of prion disease pathogenesis, mice
intraperitoneally infected with scrapie strain RML. The
primary screens identified CaMK4β and MST1 signaling
pathways as of potential interest. Targeted analyses then
tested the activation state of these pathways. CaMK4β/
CREB signaling, which promotes neuronal survival, was
activated at earlier times in scrapie-infected mice, but
returned to the levels of mock-infected mice at later
times. At these later times, MST1 signaling, which pro-
mote neuronal death, was activated (Figure 9).
The activation of CaMK4β/CREB signaling at pre-
clinical stages of prion disease had not been described.
CREB is critical to neuronal survival. CREB/cAMP re-
sponse element modulator (CREM) double knockout
mice, or mice in which CREB is inhibited by overexpres-
sion of a dominant negative mutant or inhibitory peptides,
suffer extensive neuronal loss [62-64]. Active CREB pro-
motes neuronal survival by regulating transcription of “ac-
tivity-regulated inhibitor of death” (AID) genes, including
gadd45β, gadd45γ, btg2, npas4, nr4a1, inhba, atf3, ifi202b,
serpinb2 [53,54]. CREB also regulates the transcription of
Figure 5 (See legend on next page.)
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Figure 5 CREB is expressed to higher levels in scrapie- than in mock-infected mice at 70 and 90 dpi. Targeted secondary analyses of the
NMDAR-regulated CaMK4β signaling pathway in brainstem-cerebellum, subcortical and cortical regions of scrapie-infected mice at 70, 90, 110,
130 dpi or at terminal stage of disease (TER; 155–190 dpi). (A) Expression levels of p38γ, Lyn, RSK1, CaMK4β, nNOS, CREB, and PSD-95 in the
brainstem-cerebellums of each of the three scrapie-infected mice at each time point, normalized to those in the mock-infected mice, shown by
color bars. The proteins in dashed lines were not analyzed. (B) Levels of CaMK4β and CREB in all macrodissected regions, normalized to those in
the mock-infected mice, shown as time series. Mean ± SD; n = 3. Error bars on the x-axes, range in time of onset of terminal disease. The differences in
the expression levels in scrapie- versus mock-infected mice were analyzed by two-tailed paired ratio t-test. *P < 0.05.
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[67]. High-throughput analyses have identified changes
in many mRNAs and miRNAs, including miR132-3p, in
scrapie-infected mice prior to the accumulation of PrPres
or the onset of clinical disease [68-73]. Elevated levels
of miR132-3p and AID genes (gadd45β, gadd45γ, btg2,
npas4, nr4a1) were observed at 70–110 dpi after infection
with the same scrapie strain and by the same route of in-
oculation as in the current experiments [72]. Activated
CaMK4β/CREB signaling may well promote neuronal sur-
vival early in prion infection by upregulating the expres-
sion of miR132-3p and AID genes.
CaMK4β/CREB signaling returned to the activation
levels of mock-infected mice at 110 dpi. Calcineurin reg-
ulates the activity of CaMK4 [74] and CREB [75], and el-
evated calcineurin activity was observed in scrapie-
infected mice at clinical stages of disease [19]. Moreover,
the calcineurin inhibitor FK506 prolonged survival of
scrapie-infected mice and inhibited neuronal death in
cultured neurons treated with PrP106-126 [19,76,77].
CaMK4β/CREB signaling is therefore most likely neuro-
protective in scrapie-infected mice. Decreased levels of
activated CaMK4β (P-T196) and phosphorylated CREB
(P-S133) were associated with decreased expression levels,
suggesting that degradation may be involved in downregu-
lation of this pathway. CaMK4 and CREB are degraded by
calpain, a calcium-dependent protease [78,79]. Active cal-
pain degraded CaMK4 and CREB in cultured neurons
treated with hydrogen peroxide after CREB (P-S133) de-
phosphorylation [80]. Increased levels of calpain have been
observed in in vitro and in vivo models of prion disease
[81,82], and calpain inhibition limited neuronal death
in prion-infected cultured organotypic cerebellar slices or
cultured neurons treated with PrP106-126 [81,83,84].
CaMK4β/CREB signaling activation may be inhibited in
scrapie-infected mice after 90 days by dephosphorylation
and degradation mediated by calpain. CaMK4 and CREB
are also dephosphorylated by protein phosphatase 2A
(PP2A) [85-87], the activity of which has yet to be evalu-
ated during scrapie infection.
MST1 signaling was activated at 130 dpi, which had not
been described in prion disease. MST1 has been shown to
be involved in other neurodegenerative diseases. Genetic-
ally modified mice that model amyotrophic lateralsclerosis (ALS) lose fewer neurons and survive longer if
they are knocked out of MST1 [88]. Active MST1 (P-
T183) is cleaved by active (cleaved) caspase-3 [57-60], the
levels of which are elevated in scrapie-infected mice (be-
fore the accumulation of PrPres) and in cultured neurons
or neuroblastoma cells exposed to PrP106-126 or PrPSc
[89-92]. We observed elevated levels of cleaved MST1 at
130 dpi, suggesting that it is also cleaved by caspase-3
in vivo. Although cleaved MST1 retains the T183 phos-
phorylation site, T183 phosphorylation is not required for
cleavage [56,93], and we did not detect cleaved MST1 with
the phosphorylation-specific antibody. Caspase-cleaved
MST1 translocates to the nucleus and induces chromatin
condensation by inducing phosphorylation of histone H2B
on S14 [94]. Chromatin condensation has been observed
previously in scrapie-infected GT1 cells and mice [95-98].
However, caspase-3 activation is not required for MST1
activation [56] or neuronal death in prion disease
[92,99,100].
MST1 activates FOXO3, which is otherwise maintained
in the cytosol in an inactive state by interaction with 14-3-
3 proteins [101]. Cleaved MST1 predominately localizes to
the nucleus and is therefore unable to phosphorylate
FOXO3 [102,103]. The levels of phosphorylated FOXO3
(P-S208) might have been higher (but were not statistically
different) after the levels of cleaved MST1 had returned to
those in mock-infected mice. Active FOXO3 upregulates
transcription of genes encoding pro-apoptotic proteins in-
cluding Bim (bcl-2 interacting mediator of cell death;
bcl2l11), Puma (Bcl-2-binding component 3; bbc3) and
Noxa (phorbol-12-myristate-13-acetate-induced protein 1;
pmaip1) [104-106]. The levels of Bim, Puma, bcl2l11, bbc3
and pmaip1 are elevated in scrapie-infected mice at late
stages of disease progression [72,107,108], suggesting that
neuronal death mediated by MST1 signaling could involve
FOXO3.
The CaMK4β/CREB and MST1 signaling pathways were
identified in our screens because the expression levels of
the involved protein kinases changed coordinately during
prion disease progression (Figures 5 and 7). The CaMK4β/
CREB signaling pathway promotes neuronal survival.
CaMK4β and CREB were expressed to higher levels and
activated at earlier stages of disease. Neurons may activate
this pathway to protect themselves from prion-mediated
Figure 6 (See legend on next page.)
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Figure 6 Activation of CaMK4β/CREB signaling in scrapie-infected mice early in disease. Targeted tertiary analyses of the NMDAR-regulated
CaMK4β signaling pathway in brainstem-cerebellum, subcortical and cortical regions of scrapie-infected mice at 70, 90, 110, 130 dpi or at terminal
stage of disease (TER; 155–190 dpi). (A) Levels of phosphorylated p38 (T180/Y182), Lyn (Y396), RSK1 (S380), nNOS (S847), CaMK4β (T196), and CREB
(S133) in the brainstem-cerebellums of each of the three scrapie-infected mice at each time, normalized to those in the mock-infected mice,
shown by color bars. The proteins in dashed lines were not analyzed. (B) Levels of phosphorylated CaMK4β (T196) and CREB (S133) in all
macrodissected regions, normalized to those in the mock-infected mice, shown as time series. Mean ± SD; n = 3 (Mean ± range for CaMK4β (T196)
at 90 dpi [subcortical region] and 110 dpi [brainstem-cerebellum], and CREB (S133) at 130 dpi [brainstem-cerebellum]; n = 2). Error bars on the
x-axes, range in time of onset of terminal disease. The differences in phosphorylation levels in scrapie- versus mock-infected mice were analyzed
by two-tailed paired ratio t-test. *P < 0.05; **P < 0.01.
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CREB signaling was lost and MST1 signaling was acti-
vated. Activation of MST1 signaling was associated with
lower levels of full length MST1 and FOXO3. The de-
crease in full length MST1 was two-fold greater than the
increase in the cleaved form (detected in the same blots
with the same antibody). Cleaved MST1 may be less stable
than full length MST, or full length MST1 may be proc-
essed by caspase-dependent and independent pathways.
The opposing changes in expression and activation state
suggest an attempt to prevent the neuronal death that
would result from activated MST1 signaling. The levels of
upstream kinases DLK, MKK7, and JNK2 were also lower
in scrapie-infected mice at 130 dpi, albeit only in the
brainstem-cerebellum (Figure 7). The cerebellum (in the
brainstem-cerebellum) may contain ~50% of all neurons
in an adult mouse brain [109] and loses the most neurons
in RML-infected mice, as indicated by nuclear DNA frag-
mentation [96]. The changes in the total levels of proteins
involved in the MST1 signaling pathway in each brain re-
gion may reflect the differences in the number of affected
neurons in each brain region.
The different numbers of affected neurons in each region
may also be reflected in the higher levels of total and phos-
phorylated CaMK4β in the brainstem-cerebellum than in
the subcortical or cortical regions. Regardless of absolute
numbers, higher levels of total and phosphorylated CREB
were expressed in all brain regions. Although CaMK4
(P-T196) could also be responsible for CREB (P-S133)
phosphorylation, there were no differences in the levels of
activated CaMK4 (P-T196) in scrapie- versus mock-
infected mice (data not shown). CREB is also phosphory-
lated on S133 by other protein kinases, including RSK,
cAMP-dependent protein kinase (PKA), and mitogen-
activated protein kinase-activated protein kinase 2 (MAP-
KAPK2) (for a review, see [110]). There was no correlation
between the levels of active RSK1 (P-S380) and phosphory-
lated CREB (P-S133). We did not evaluate other protein ki-
nases upstream of CREB because they were not identified
in the primary screening. However, CREB may well be acti-
vated independently of CaMK4β in the cortical region or
subcortical region of scrapie-infected mice.
The data presented cannot discriminate whether the
observed changes in signaling pathways are a cause or aconsequence of the pathology. Neither can discriminate
whether they result from a loss of PrPC function, a gain of
PrPres function, or an altered signaling function resulting
from the progressive PrPC misfolding into PrPres. More-
over, the dysregulation could have been directly triggered
by PrPres or PrPC acting on the neurons, or mediated by
the glial alterations that occur during disease progression.
The data presented does not resolve either whether the
observed signaling changes are specific for prion diseases,
or common to other neurodegenerative diseases. Future
work will have to address these possibilities.
Conclusion
We used a kinomics approach to identify two dysregu-
lated signaling pathways, involved in neuronal survival/
death, in scrapie-infected mice. Their dysregulation at
different times during disease is temporally consistent with
the neuronal loss during prion disease. Our findings iden-
tified novel signaling involved in prion-mediated neuronal
death in vivo and identify potential targets for interven-
tion. It is possible to test now the roles of these signaling
pathways in prion disease, as well-characterized inhibitors
of several of these proteins are available.
Materials and methods
Ethics statement
All of the procedures involving live animals were approved
by the Canadian Science Centre for Human and Animal
Health – Animal Care Committee (CSCHAH-ACC) or the
University of British Columbia Animal Care Committee
according to the guidelines set by the Canadian Council
on Animal Care. The approval identifications for this
study were animal use document (AUD)#H-08-009 and
AUD#H-11-020.
Animals and sample collection
CD1 mice (Charles River Laboratories) between 4–6
weeks of age were infected intraperitoneally with the
Rocky Mountain Laboratory (RML) mouse-adapted strain
of scrapie. The inoculums consisted of 200 μl of 1% brain
homogenate in PBS from either clinically ill or normal
control mice. Animals were sacrificed at 70, 90, 110,
130 days post infection (dpi) and terminal disease (155–
190 dpi). Clinical signs depicting terminal disease
Figure 7 (See legend on next page.)
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Figure 7 MST1 and FOXO3 are expressed to lower levels in scrapie-infected mice at 130 dpi. Targeted secondary analyses of the MST1
signaling pathway in brainstem-cerebellum, subcortical and cortical regions of scrapie-infected mice at 70, 90, 110, 130 dpi or at terminal stage of
disease (TER; 155–190 dpi). (A) Levels of DLK, MKK7, JNK2, MST1, and FOXO3 in the brainstem-cerebellums of three scrapie-infected mice at each
time point, normalized to those in the mock-infected mice, shown by color bars. (B) Protein levels in all macrodissected regions, normalized to
those in mock-infected mice, shown as time series. Mean ± SD; n = 3 (Mean ± range for FOXO3 at 90 dpi [brainstem-cerebellum] and TER
[brainstem-cerebellum, subcortical region]; n = 2). Error bars on the x-axes, range in time of onset of terminal disease. The differences in expression
levels in scrapie- versus mock-infected mice were analyzed by two-tailed paired ratio t-test. *P < 0.05; **P < 0.01; ****P < 0.0001.
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or more and ataxia. Brain samples were collected and
macrodissected into three sections, (i) cortical, (ii) subcor-
tical (including thalamus, hypothalamus and hippocam-
pus) and (iii) brainstem-cerebellum. Each section was
flash frozen using a dry ice/methanol mixture and stored
at −80°C until processing. A total of 3 scrapie- and 3
mock-infected samples were collected per time point.
Brain homogenization
All procedures were performed at 4°C or on ice.
Weighed frozen brainstem-cerebellum, subcortical, and
cortical regions from mock- or scrapie-infected mice
were homogenized in 3 mL of freshly prepared lysis buf-
fer (20 mM MOPS [pH 7.0], 2 mM EGTA, 5 mM
EDTA, 1% Nonidet P-40, 0.01% phosphatase inhibitor
cocktail [Pierce, Rockford, Illinois, USA], 0.02% protease
inhibitor cocktail [Sigma-Aldrich, St. Louis, Missouri,
USA], 10 mM DTT, pH 7.2) [111] per 250 mg of brain,
using a tissue homogenizer with disposable tips (TH and
hard tissue OMNI tip, respectively; OMNI International,
Kennesaw, Georgia, USA). Brain homogenates were passed
twice through a 21 gauge needle, sonicated five times for
20 s intervals at 88 W output (431C1 cup horn probe, S-
4000 sonicator; Qsonica, Newtown, Connecticut, USA),
and pre-cleared by centrifugation for 30 min at 14,000 × g
(JLA 16.250 BC rotor, Avanti J-E centrifuge; Beckman/
Coulter, Brea, California, USA). Approximately 200 μL ali-
quots of supernatant were aliquoted into 1.5 mL tubes,
snap frozen in liquid nitrogen and stored at −80°C.
Protein quantitation
Protein concentration was determined by Bradford’s assay
(Bio-Rad Laboratories, Hercules, California, USA). Protein
concentration and equal sample loading was re-tested in
preliminary sodium dodecyl sulfate polyacrylamide gel
electrophoresis (SDS-PAGE). Brain homogenates were
mixed with an equal volume of 2X SDS loading buffer
(125 mM Tris-Cl [pH 6.8], 20% glycerol, 4% SDS, 0.005%
bromophenol blue, 260 mM DTT) and denatured by incu-
bation at 100°C for 10 min. Afterward, 15-well 8% SDS-
PAGE gels (Mini-PROTEAN; Bio-Rad Laboratories) were
loaded with 40 μg of denatured protein per linear cm of
well (running buffer; 190 mM glycine, 24.8 mM Tris, 0.1%
SDS, pH 8.3). Proteins were run through the stacking gelat 50 V, and then resolved for 90 min at 100 V, always at
room temperature. Proteins were stained with Coomassie
blue G-250 (Bio-Safe Coomassie; Bio-Rad Laboratories)
according to the manufacturer’s instructions. Signal from
Coomassie-stained protein was detected using an Odyssey
infrared imaging system (LI-COR Biosciences, Lincoln,
Nebraska, USA) in the 700 nm channel and quantitated
using Odyssey 3.0 software (LI-COR Biosciences). Protein
amounts were calculated relative to a pre-quantitated
standard brain homogenate.
Sodium phosphotungstic acid precipitation
Sodium phosphotungstic acid (NaPTA) precipitation was
adapted from [112,113]. One milligram of mouse brain
homogenate was mixed with an equal volume of 4% so-
dium lauroylsarcosine (sarkosyl) in PBS. Samples were in-
cubated for 10 min at 37°C with constant agitation
(1000 rpm, Thermomixer; Eppendorf, Hamburg, Germany).
A 37°C NaPTA solution (PBS, 4% NaPTA, 170 mM MgCl2,
pH 7.4) was then added to a final concentration of 0.3%
NaPTA. Samples were incubated for 60 min at 37°C with
constant agitation (1000 rpm, Thermomixer; Eppendorf),
then centrifuged at 37°C for 30 min at 16,000 × g (FA-45-
18-11 rotor, 5418 microfuge; Eppendorf). Pellets were re-
suspended in 5 μL of 0.1% sarkosyl in PBS and digested
with 20 μg of proteinase K (PK; in 0.01 M CaCl2) (Roche,
Indianapolis, Indiana, USA) for 30 min at 37°C with a brief
vortex after 15 min [114]. Digestion was stopped and PK-
resistant protein was denatured by quickly adding an ap-
proximately equal volume 5X SDS loading buffer (300 mM
Tris-Cl [pH 6.8], 50% glycerol, 25% β-mercaptoethanol,
10% SDS, 1% bromophenol blue), and immediately incubat-
ing at 100°C for 10 min. Samples were resolved by SDS-
PAGE and analyzed by Western blot.
Western blot
All procedures were performed at room temperature
and all washes were performed using gentle rocking, un-
less otherwise indicated.
PrPres was analyzed in 1.0 mg of NaPTA-enriched, PK-
treated mouse brain homogenate using 15-well 12% SDS-
PAGE gels (NuPAGE Novex Bis-Tris; Life Technologies
Inc., Carlsbad, California, USA). The running buffer
(50 mM MOPS, 50 mM Tris, 1 mM EDTA, 0.1% SDS,
pH 7.7) within the upper (cathode) chamber contained
Figure 8 (See legend on next page.)
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Figure 8 Activation of MST1 in scrapie-infected mice at late stages of disease. Targeted tertiary analyses of MST1 signaling in brainstem-
cerebellum, subcortical region, and cortical region of scrapie-infected mice at 70, 90, 110, 130 dpi or at terminal stage of disease (TER; 155–190 dpi).
(A) Levels of phosphorylated JNK (T183/Y185), MST1 (T183), FOXO3 (S208), and cleaved MST1, in the brainstem-cerebellums of each of the three
scrapie-infected mice at each time point, normalized to those in the mock-infected mice, shown by color bars. The proteins in dashed lines were not
analyzed. (B) Phosphorylation levels in all brains regions, normalized to those in the mock-infected mice, shown as time series. Mean ± SD; n = 3
(Mean ± range for MST1 (T183) at 110 dpi [subcortical region] and TER [brainstem-cerebellum], and FOXO3 (S208) at 130 dpi [brainstem-cerebellum]
and TER [cortical region]; n = 2). Error bars on the x-axes, range in time of onset of terminal disease. The differences in the phosphorylation levels, or
levels of cleaved MST1, in scrapie- versus mock-infected mice were analyzed by two-tailed paired ratio t-test. *(#, cleaved MST1), P < 0.05.
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stacking gel at 60 V, and then resolved for 2.5 h at 120 V.
Afterward, polyvinylidene fluoride (PVDF) membranes
(Immuno-Blot, 0.2 μm; Bio-Rad Laboratories) were soaked
in methanol for 2 min, then equilibrated in transfer buffer
(190 mM glycine, 24.5 mM Tris, 10% methanol) for
20 min. Filter paper (2 sheets/membrane) were equili-
brated in transfer buffer for 5 min. Proteins were trans-
ferred at 4°C for 2 h at 30 V. After transfer, membranes
were dried, soaked in methanol for 2 min and washed
twice for 10 min each in Tris-buffered saline (TBS;
140 mM NaCl, 3 mM KCl, 25 mM Tris, pH 7.6). Mem-
branes were blocked for 1 h in TBST (TBS/0.1% Tween-
20) with 5% milk, then probed with PrP primary antibody
(clone SAF83; a kind gift from Dr. Deborah McKenzie,
University of Alberta) diluted to 1:10,000 in TBST with
5% milk for 18 h at 4°C. Afterward, membranes were
washed with TBST once for 5 min and thrice for 10 min
each. Membranes were incubated with goat anti-mouse
horseradish peroxidase (HRP)-labeled secondary antibody
(Bio-Rad Laboratories) diluted to 1:40,000 in TBST with
5% milk for 1 h. Membranes were washed in TBST once
for 5 min and thrice for 15 min each, incubated for 5 min
with enhanced chemiluminescent substrate (SuperSignal
West Femto; Pierce) and then exposed to film (Super RX;
Fujifilm, Tokyo, Japan). Exposed film was developed andFigure 9 A model for the activation of signaling pathways involved in
Relative activation states of CaMK4β/CREB (red line) and MST1 (green line)
in grey. Between 90 and 130 dpi, there is a switch from signaling involved
neuronal death (activated MST1). Adapted from [72] (Figure 7).scanned (CanoScan LiDE 200; Canon, Tokyo, Japan).
Signal was quantitated using ImageJ (Version 1.47c;
National Institutes of Health, Bethesda, Maryland, USA).
To analyze GFAP and total PrP, brain homogenates were
mixed with a one-fourth volume of 5X SDS loading buffer.
Then, 100 μg of denatured protein was loaded per linear
cm onto 15-well 12% SDS-PAGE gels (Mini-PROTEAN;
Bio-Rad Laboratories). Proteins were run through the
stacking gel at 50 V, and then resolved for 100 min at
100 V. Afterward, gels were equilibrated in transfer buffer
(384 mM glycine, 49.6 mM Tris, 20% methanol, 0.01%
SDS) [115] for 30 min. PVDF membranes and filter paper
(2 sheets/membrane) were also equilibrated in transfer
buffer for 20 and 5 min, respectively. Proteins were trans-
ferred for 23 h at 4°C; 1 h at 54 mA, 4 h at 189 mA, 8 h at
270 mA and 10 h at 378 mA. Membranes were blocked
with 10% blocking buffer (Sigma-Aldrich) for 1 h and
probed simultaneously with primary antibodies specific
for PrP (clone SAF83) and GFAP (Abcam Inc., Cambridge,
Massachusetts, USA) diluted to 1:10,000 and 1:20,000 in
10% blocking buffer with 0.1% Tween-20, respectively,
for 18 h at 4°C. Afterward, membranes were washed with
TBST once for 5 min and thrice for 10 min each.
Membranes were then incubated for 1 h with donkey anti-
mouse IRDye 680- (LI-COR Biosciences) and donkey anti-
rabbit IRDye 800- (LI-COR Biosciences) labeled secondaryneuronal survival and death during scrapie pathogenesis.
signaling in scrapie-infected mice during disease progression, indicated
in neuronal survival (activated CaMK4β/CREB) to that involved in
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0.1% Tween-20 and 0.01% SDS. Afterward, membranes
were washed in TBST thrice for 10 min each, and once
with TBS for 5 min. Signal from pre-stained protein stan-
dards and IRDye 680-labeled secondary antibody was de-
tected at 700 nm using an Odyssey infrared imaging
system (LI-COR Biosciences). Signal from IRDye 800-
labeled secondary antibody was detected at 800 nm. Signal
was quantitated using Odyssey 3.0 software (LI-COR Bio-
sciences). Membranes were then stained with Coomassie
blue R-250 (Bio-Rad Laboratories) for 10 min before
destaining with 40% methanol in 10% glacial acetic acid
thrice for 10 min each, or until excess stain was removed.
Signal from Coomassie-stained protein was detected at
700 nm using the Odyssey and quantitated using Odyssey
3.0 software.
For multiplex Western blots, brain homogenates were
mixed with an equal volume of 2X, or one-fifth volume
of 6X (375 mM Tris-Cl [pH 6.8], 60% glycerol, 12% SDS,
0.015% bromophenol blue, 780 mM DTT), SDS-PAGE
loading buffer, and then 200 μg of denatured protein
was loaded per linear cm of single-well 8% SDS-PAGE
gels (Mini-PROTEAN; Bio-Rad Laboratories). Proteins
were resolved as described for protein quantitation and
transferred as described for Western blots of GFAP and
total PrP. Dried membranes were probed immediately or
stored at −30°C. All multiplex Western blots were per-
formed in three sets, each composed of one membrane
from a mock- and one from a scrapie-infected mouse
euthanized at 70, 90, 110, 130 dpi, or at terminal stage
of disease. Membranes were blocked for 1 h with 10%
blocking buffer (Sigma-Aldrich) for evaluation of total
protein levels, or in 3% BSA (Rockland, Gilbertsville,
Pennsylvania, USA) for evaluation of phosphorylation
levels. Membranes were rinsed briefly with TBS and po-
sitioned within a 24-lane multi-screen apparatus (MPX;
LI-COR Biosciences). Combinations of primary anti-
bodies were diluted in 10% blocking buffer or 3% BSA,
as appropriate, with 0.1% Tween-20. One hundred sixty
microliters of each antibody dilution was loaded in each
lane of the multi-screen apparatus. After incubation for
18 h at 4°C, membranes were briefly washed once with
TBST within the multi-screen apparatus then removed
from the apparatus and further washed in TBST, once
for 5 min and four times for 15 min each. Membranes were
incubated with secondary antibody diluted to 1:20,000 in
10% blocking buffer or 3% BSA, as appropriate, with 0.1%
Tween-20 and 0.01% SDS for 1 h. Mouse monoclonal pri-
mary antibodies were detected with donkey anti-mouse
IRDye 680-labeled secondary antibody. Rabbit or goat pri-
mary polyclonal primary antibodies were detected with
donkey anti-rabbit or donkey anti-goat IRDye 800-labeled
secondary antibody (LI-COR Biosciences), respectively.
Membranes were washed in TBST four times for 15 mineach and once with TBS for 5 min. Signal from IRDye
680- and IRDye 800-labeled secondary antibody was de-
tected at 700 and 800 nm, respectively, using the Odyssey
system. Signal was quantitated using Odyssey 3.0 software.
Membranes from scrapie-infected mice were stripped
(only once) together and in parallel with the membranes
from the mock-infected mice from the same set, under
conditions to minimize protein loss [116]. Membranes
were stripped with mild stripping buffer (25 mM glycine,
1% SDS, pH 2.0) once for 5 min and four times for
15 min each, then with harsh stripping buffer (50 mM
Tris-Cl [pH 7.0], 2% SDS, 50 mM DTT) [117] once for
15 min at 37°C. Afterward, stripped membranes were
washed with TBST once and TBS once for 5 min each,
then blocked and reprobed with a second set of primary
antibodies as described.
Hierarchical cluster analysis
For each set, the densitometric data from the primary
multiplex Western blots of brainstem-cerebellum ho-
mogenates of scrapie-infected mice was normalized to
that from the mock-infected mice. Relative protein
kinase expression levels were then log2 transformed and
analyzed with Gene Cluster 3.0 [118] using Euclidean
distance and complete linkage. Java Treeview was used
to present the clusters [119].
Statistical analyses
All data was analyzed using Prism (Version 5.0f; GraphPad
Software Inc., La Jolla, California, USA). The targeted
Western blots were performed in three experimental sets
on different days. Each set encompassed one scrapie- and
one mock-infected mouse from each time point. The ratios
from each set were thus analyzed by paired t-test. The ra-
tios were log transformed before analyses to transform the
increased and decreased ratios (ratios greater or smaller
than 1, respectively) to proportional values. For nonlinear
regression analyses, curves of the normalized total and
phosphorylation protein levels in scrapie-infected mice
were compared to no changes (a line with intercept = 1,
slope = 0), representing the levels in mock-infected mice,
using a replicates test for lack-of-fit.
Additional files
Additional file 1: Table S1. Accession numbers for the 130 protein
kinases and 9 regulatory subunits analyzed in the primary multiplex
Western blots. One hundred and twenty-four protein kinases or
regulatory subunits included in our multiplex Western blots were
detected in 200 μg of mouse brain homogenate per linear well cm. The
other 15 (indicated by the asterisks) were detected in multiplex Western
blots using an equivalent amount of lysate from cycling 3T3 mouse
fibroblasts. The human accession number for each protein is indicated.
Additional file 2: Figure S1. CREB is expressed and phosphorylated to
higher levels in the subcortical and cortical regions of scrapie- than
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p38γ, Lyn, RSK1, CaMK4β, nNOS, CREB, and PSD-95 (A) or levels of
phosphorylated p38 (T180/Y182), Lyn (Y396), RSK1 (S380), nNOS (S847),
CaMK4β (T196), and CREB (S133) (B) in the subcortical and cortical regions
of each of the three scrapie-infected mice each time point shown by
color bars. The proteins in dashed lines were not analyzed.
Additional file 3: Figure S2. Lower levels of MST1 and FOXO3 are
phosphorylated to higher levels in the subcortical and cortical regions of
scrapie-infected mice at 130 dpi. The normalized expression levels of
DLK, MKK7, JNK2, MST1 and FOXO3 (A) or levels of phosphorylated JNK
(T183/Y185), MST1 (T183), FOXO3 (S208), and cleaved MST1 (B) in the
subcortical and cortical regions of each of the three scrapie-infected mice
at each time point shown by color bars. The proteins boxed in dashed
lines were not analyzed.
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